ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer

Links shared publicly online about this topic.

1,119
total visits

ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer

A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).

View full resource at news-medical.net

Tags: Cancer, Chemotherapy, Ovarian Cancer, Drug, Women's Health, Obstetrics & Gynecology, News